- Clinical Study
- Obesity and Hyperglycemia in Korean Men with Klinefelter Syndrome: The Korean Endocrine Society Registry
-
Seung Jin Han, Kyung-Soo Kim, Wonjin Kim, Jung Hee Kim, Yong-ho Lee, Ji Sun Nam, Ji A Seo, Bu Kyung Kim, Jihyun Lee, Jin Ook Chung, Min-Hee Kim, Tae-Seo Sohn, Han Seok Choi, Seong Bin Hong, Yoon-Sok Chung
-
Endocrinol Metab. 2016;31(4):598-603. Published online December 20, 2016
-
DOI: https://doi.org/10.3803/EnM.2016.31.4.598
-
-
4,451
View
-
32
Download
-
18
Citations
-
 Abstract
 PDF PubReader  Crossref - TDM
- Background
The aim of this study was to investigate the prevalence of obesity in Korean men with Klinefelter syndrome (KS) and the associated risk factors for obesity and hyperglycemia. MethodsData were collected retrospectively from medical records from 11 university hospitals in Korea between 1994 and 2014. Subjects aged ≥18 years with newly diagnosed KS were enrolled. The following parameters were recorded at baseline before treatment: chief complaint, height, weight, fasting glucose level, lipid panel, blood pressure, testosterone, luteinizing hormone, follicle-stimulating hormone, karyotyping patterns, and history of hypertension, diabetes, and dyslipidemia. ResultsData were analyzed from 376 of 544 initially enrolled patients. The rate of the 47 XXY chromosomal pattern was 94.1%. The prevalence of obesity (body mass index ≥25 kg/m2) in Korean men with KS was 42.6%. The testosterone level was an independent risk factor for obesity and hyperglycemia. ConclusionObesity is common in Korean men with KS. Hypogonadism in patients with KS was associated with obesity and hyperglycemia.
-
Citations
Citations to this article as recorded by  - A dual-center study of predictive factors for sperm retrieval through microdissection testicular sperm extraction and intracytoplasmic sperm injection outcomes in men with non-mosaic Klinefelter syndrome
Jong Hyeun Baeck, Tae Jin Kim, Tae Heon Kim, Seung-Ryeol Lee, Dong Soo Park, Hwang Kwon, Ji Eun Shin, Dong Hyeon Lee, Young Dong Yu
Investigative and Clinical Urology.2023; 64(1): 41. CrossRef - Cardiorespiratory fitness in adolescents and young adults with Klinefelter syndrome – a pilot study
Julia Spiekermann, Kathrin Sinningen, Beatrice Hanusch, Michaela Kleber, Michael M. Schündeln, Cordula Kiewert, Heide Siggelkow, Jakob Höppner, Corinna Grasemann
Frontiers in Endocrinology.2023;[Epub] CrossRef - Metabolic Profile in a Cohort of Young Sicilian Patients with Klinefelter’s Syndrome: The Role of Irisin
Stefano Radellini, Valentina Guarnotta, Vincenzo Sciabica, Giuseppe Pizzolanti, Carla Giordano, Vito Angelo Giagulli
International Journal of Endocrinology.2022; 2022: 1. CrossRef - Metabolic and Nutritional Aspects in Paediatric Patients with Klinefelter Syndrome: A Narrative Review
Chiara Mameli, Giulia Fiore, Arianna Sangiorgio, Marta Agostinelli, Giulia Zichichi, Gianvincenzo Zuccotti, Elvira Verduci
Nutrients.2022; 14(10): 2107. CrossRef - Klinefelter syndrome in an adolescent with severe obesity, insulin resistance, and hyperlipidemia, successfully treated with testosterone replacement therapy
Shota Fukuhara, Jun Mori, Hisakazu Nakajima
Clinical Pediatric Endocrinology.2021; 30(3): 127. CrossRef - Glucose metabolic disorder in Klinefelter syndrome: a retrospective analysis in a single Chinese hospital and literature review
Shixuan Liu, Tao Yuan, Shuoning Song, Shi Chen, Linjie Wang, Yong Fu, Yingyue Dong, Yan Tang, Weigang Zhao
BMC Endocrine Disorders.2021;[Epub] CrossRef - What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of ‘Internal Medicine for Rare Genetic Syndromes’
Anna G. W. Rosenberg, Minke R. A. Pater, Karlijn Pellikaan, Kirsten Davidse, Anja A. Kattentidt-Mouravieva, Rogier Kersseboom, Anja G. Bos-Roubos, Agnies van Eeghen, José M. C. Veen, Jiske J. van der Meulen, Nina van Aalst-van Wieringen, Franciska M. E. H
Journal of Clinical Medicine.2021; 10(22): 5457. CrossRef - Klinefelter Syndrome and Diabetes
Mark J. O’Connor, Emma A. Snyder, Frances J. Hayes
Current Diabetes Reports.2019;[Epub] CrossRef - Endocrine aspects of Klinefelter syndrome
Adriana Herrera Lizarazo, Michelle McLoughlin, Maria G. Vogiatzi
Current Opinion in Endocrinology & Diabetes and Obesity.2019; 26(1): 60. CrossRef - Sex differences in metabolism and cardiometabolic disorders
Karthickeyan Chella Krishnan, Margarete Mehrabian, Aldons J. Lusis
Current Opinion in Lipidology.2018; 29(5): 404. CrossRef - Klinefelter Syndrome: Integrating Genetics, Neuropsychology, and Endocrinology
Claus H Gravholt, Simon Chang, Mikkel Wallentin, Jens Fedder, Philip Moore, Anne Skakkebæk
Endocrine Reviews.2018; 39(4): 389. CrossRef - Sex differences in obesity, lipid metabolism, and inflammation—A role for the sex chromosomes?
Temeka Zore, Maria Palafox, Karen Reue
Molecular Metabolism.2018; 15: 35. CrossRef - Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives
Andrea Salzano, Roberta D’Assante, Liam M. Heaney, Federica Monaco, Giuseppe Rengo, Pietro Valente, Daniela Pasquali, Eduardo Bossone, Daniele Gianfrilli, Andrea Lenzi, Antonio Cittadini, Alberto M. Marra, Raffaele Napoli
Endocrine.2018; 61(2): 194. CrossRef - Síndrome de Klinefelter y riesgo cardiovascular
A. Yamaguchi, P. Knoblovits
Hipertensión y Riesgo Vascular.2018; 35(4): 195. CrossRef - Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef - Sex differences in obesity: X chromosome dosage as a risk factor for increased food intake, adiposity and co-morbidities
Karen Reue
Physiology & Behavior.2017; 176: 174. CrossRef - Klinefelter Syndrome with Morbid Obesity Before Bariatric Surgery: A Case Report
Parisa Janmohammadi, Gholamreza Mohammadi-Farsani, Hana Arghavani, Mahmoud Arshad, Tayebeh Mokhber
Journal of Minimally Invasive Surgical Sciences.2017;[Epub] CrossRef - Klinefelter Syndrome and Metabolic Disorder
Ji Cheol Bae
Endocrinology and Metabolism.2016; 31(4): 535. CrossRef
- Bone Metabolism
- Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
-
Wonjin Kim, Yoonjung Chung, Se Hwa Kim, Sehee Park, Jae Hyun Bae, Gyuri Kim, Su Jin Lee, Jo Eun Kim, Byeong-Woo Park, Sung-Kil Lim, Yumie Rhee
-
Endocrinol Metab. 2015;30(1):58-64. Published online March 27, 2015
-
DOI: https://doi.org/10.3803/EnM.2015.30.1.58
-
-
3,381
View
-
28
Download
-
14
Citations
-
Abstract
PDFPubReader Crossref - TDM
- Background
Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin levels in Korean women with breast cancer who were treated with an AI. MethodsWe included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly assigned to take either 5 mg alendronate with 0.5 µg calcitriol (n=46), or placebo (n=44) for 6 months. ResultsPostmenopausal women with breast cancer had significantly higher sclerostin levels compared to those in premenopausal women (27.8±13.6 pmol/L vs. 23.1±4.8 pmol/L, P<0.05). Baseline sclerostin levels positively correlated with either lumbar spine or total hip bone mineral density only in postmenopausal women (r=0.218 and r=0.233; P<0.05, respectively). Serum sclerostin levels increased by 39.9%±10.2% 6 months after AI use in postmenopausal women; however, no difference was observed between the alendronate and placebo groups (39.9%±10.2% vs. 55.9%±9.13%, P>0.05). ConclusionSerum sclerostin levels increased with absolute deficiency of residual estrogens in postmenopausal women with endocrine-responsive breast cancer who underwent AI therapy with concurrent bone loss.
-
Citations
Citations to this article as recorded by - Voluntary Wheel Running Partially Compensates for the Effects of Global Estrogen Receptor-α Knockout on Cortical Bone in Young Male Mice
Rebecca K. Dirkes, Nathan C. Winn, Thomas J. Jurrissen, Dennis B. Lubahn, Victoria J. Vieira-Potter, Jaume Padilla, Pamela S. Hinton
International Journal of Molecular Sciences.2021; 22(4): 1734. CrossRef - Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease
Manish Adhikari, Jesús Delgado-Calle
Current Osteoporosis Reports.2021; 19(3): 247. CrossRef - Gestational and lactational exposure to BPA or BPS has minimal effects on skeletal outcomes in adult female mice
Rebecca K. Dirkes, Rebecca J. Welly, Jiude Mao, Jessica Kinkade, Victoria J. Vieira-Potter, Cheryl S. Rosenfeld, Pamela S. Bruzina
Bone Reports.2021; 15: 101136. CrossRef - Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model
Enas A. Fouad-Elhady, Hadeer A. Aglan, Rasha E. Hassan, Hanaa H. Ahmed, Gilane M. Sabry
Heliyon.2020; 6(2): e03341. CrossRef - Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer
Sung Hye Kong, Jung Hee Kim, Sang Wan Kim, Chan Soo Shin
Journal of Bone and Mineral Metabolism.2020; 38(5): 730. CrossRef - Global estrogen receptor-α knockout has differential effects on cortical and cancellous bone in aged male mice
Rebecca K. Dirkes, Nathan C. Winn, Thomas J. Jurrissen, Dennis B. Lubahn, Victoria J. Vieira-Potter, Jaume Padilla, Pamela S. Hinton, Vance L. Trudeau
FACETS.2020; 5(1): 328. CrossRef - The Emerging Role of Osteocytes in Cancer in Bone
Emily G Atkinson, Jesús Delgado-Calle
JBMR Plus.2019; 3(3): e10186. CrossRef - Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results
Katsuhiko Nakatsukasa, Hiroshi Koyama, Yoshimi Ouchi, Hisako Ono, Kouichi Sakaguchi, Takayuki Matsuda, Makoto Kato, Takashi Ishikawa, Kimito Yamada, Mana Yoshimura, Kei Koizumi, Teruhisa Sakurai, Hideo Shigematsu, Shunji Takahashi, Shinichiro Taira, Masat
Breast Cancer.2019; 26(1): 106. CrossRef - Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
Kristina Bojanić, Ines Bilić Ćurčić, Lucija Kuna, Tomislav Kizivat, Robert Smolic, Nikola Raguž Lučić, Kristina Kralik, Vatroslav Šerić, Gordana Ivanac, Sandra Tucak-Zorić, Aleksandar Včev, Martina Smolić
Journal of Clinical Medicine.2018; 7(9): 287. CrossRef - Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Peyman Hadji, Matti S. Aapro, Jean-Jacques Body, Michael Gnant, Maria Luisa Brandi, Jean Yves Reginster, M. Carola Zillikens, Claus-C. Glüer, Tobie de Villiers, Rod Baber, G. David Roodman, Cyrus Cooper, Bente Langdahl, Santiago Palacios, John Kanis, Nass
Journal of Bone Oncology.2017; 7: 1. CrossRef - Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice
Abul Kalam, Sushama Talegaonkar, Divya Vohora
Molecular and Cellular Endocrinology.2017; 440: 34. CrossRef - Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease
Michelle M. McDonald, Jesus Delgado-Calle
Current Osteoporosis Reports.2017; 15(6): 532. CrossRef - Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexene diepoxide treated ovotoxic female mice
Abul Kalam, Sushama Talegaonkar, Divya Vohora
Fundamental & Clinical Pharmacology.2016; 30(5): 429. CrossRef - Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment
Hyo Min Jeong, Sun Wook Cho, Serk In Park
Endocrinology and Metabolism.2016; 31(4): 485. CrossRef
- A Case of Latent Autoimmune Diabetes in Adults Developed after Surgical Cure of Growth Hormone Secreting Pituitary Tumor.
-
Wonjin Kim, Jung Ho Kim, Youngsook Kim, Ji Hye Huh, Su Jin Lee, Mi Sung Park, Eun Yeong Choe, Jeong Kyung Park, Myung Won Lee, Jae Won Hong, Byung Wan Lee, Eun Seok Kang, Bong Soo Cha, Eun Jig Lee, Hyun Chul Lee
-
Endocrinol Metab. 2012;27(4):318-322. Published online December 20, 2012
-
DOI: https://doi.org/10.3803/EnM.2012.27.4.318
-
-
Abstract
PDF
- Acromegaly is generally caused by a benign growth hormone (GH)-secreting pituitary adenoma. It is characterized by a wide range of complications; cardiovascular, respiratory, bone and joint, and metabolic complications. Among them, impaired glucose tolerance and diabetes mellitus, due to GH-induced insulin resistance, has been reported in approximately 16-46% and 19-56%. They are usually improved following the treatment of acromegaly, surgical or medical therapy. We report a first case of 36-year-old man who was paradoxically diagnosed with GAD antibody positive latent autoimmune diabetes in adults (LADA) after the surgical cure of acromegaly.
|
KES
